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Abstract
Background: Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia
patients is associated with different types of transcript proteins. In this study we have seen the
association of HLA genes with different types of bcr-abl transcripts. The association could predict
the bcr-abl peptide presentation by particular HLA molecules.
Methods: The study included a total of 189 patients of mixed ethnicity with chronic myelogenous
leukemia and acute lymphocytic leukemia who were being considered for bone marrow
transplantation. Typing of bcr-abl transcripts was done by reverse transcriptase PCR method. HLA
typing was performed by molecular methods. The bcr-abl and HLA association was studied by
calculating the relative risks and chi-square test.
Results: Significant negative associations (p < 0.05) were observed with HLA-A*02 (b2a2, e1a2), -
A*68 (b2a2, b3a2, e1a2), -B*14 (b2a2, b3a2, e1a2), -B*15 (b2a2, b3a2), -B*40 (b2a2), -DQB1*0303
(b2a2, b3a2), -DQB1*0603 (b2a2), -DRB1*0401 (e1a2), -DRB1*0701 (b3a2), and -DRB1*1101
(b2a2).
Conclusions: The negative associations of a particular bcr-abl transcript with specific HLA alleles
suggests that these alleles play a critical role in presenting peptides derived from the chimeric
proteins and eliciting a successful T-cell cytotoxic response. Knowledge of differential associations
between HLA phenotypes and bcr-abl fusion transcript types would help in developing better
strategies for immunization with the bcr-abl peptides against t(9;22) (q34;q11)-positive leukemia.
Background
The t(9;22) (q34;q11) translocation seen in 90% of
patients with chronic myelogenous leukemia (CML) and
about 10% patients with acute lymphocytic leukemia
(ALL) results in juxtaposition of the 3' segment of the c-abl
proto-oncogene on chromosome 9 with the 5' segment on
the bcr gene on chromosome 22 [1-6]. Breaks in c-abl gene
generally involve exon 2, also known as a2. Breaks in the
bcr occur in one of the three following regions: the major
breakpoint cluster region (M-bcr), the minor breakpoint
cluster region (m-bcr) or the micro breakpoint cluster
region (µ-bcr) [7]. Breakpoints occurring in m-bcr involve
introns 13 and 14 and join exon 13 or 14 with abl, result-
ing in the fusion transcripts e13a2 (also known as b2a2)
and e14a2 (also known as b3a2), respectively. These tran-
scripts lead to production of a 8.5-kb transcript coding for
a 210-kD chimeric protein (p210) [8,9]. Breakpoints in
m-bcr involve the first intron of bcr, exon 1 joins with abl,
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resulting in a smaller fusion transcript, e1a2, that codes
for a 190-kD protein (p190) [10]. Breakpoints in the µ-bcr
involve intron 19, the joining of exon 19 with abl results
in a fusion transcript e19a2, that codes for a 230-kD pro-
tein (p230) [11]. Although tyrosine kinase is activated in
all  bcr-abl  fusion transcripts, the p190 form has been
shown to have more transforming potential than p210 in
vitro and in vivo [12-14]. Fusion transcripts b3a2 and
b2a2, which are translated into p210, account for the
majority of CML cases, while the fusion transcript e1a2,
which is translated into p190, is seen primarily in t(9;22)-
positive ALL and the blastic phase of CML [10,15]. The
rare fusion transcript e19a2, resulting in p230, is associ-
ated primarily with the entity known as chronic neu-
trophilic leukemia [16].
Several reports indicate an association between t(9;22)
(q34;q11) and different human leukocyte antigen (HLA)
alleles. This association suggests a possible role for T-cell
cytotoxicity in the pathogenesis of diseases linked to bcr-
abl fusion proteins resulting from t(9;22) (q34;q11). Dif-
ferent HLA alleles have different predilections for the
sequence of peptides they can present to T cells. In order
to elicit a T-cell response, a peptide must bind to the HLA
molecule prior to its presentation to the T cell. Since a
given HLA allele can bind and present only peptides with
certain sequence constraints, the ability of an individual
to elicit a successful T-cell cytotoxic response to cells car-
rying foreign or newly mutated proteins depends on the
set of HLA alleles that individual has inherited. Thus, indi-
viduals carrying certain HLA alleles capable of binding
peptides derived from bcr-abl  fusion transcripts can in
principle be considered to have a biological advantage in
fighting the disease over individuals lacking these particu-
lar HLA alleles.
In studying the association between the distribution of
HLA alleles in patients with different types of bcr-abl tran-
scripts, a positive association suggests that a particular
HLA allele does not effectively bind and present peptides
derived from a given bcr-abl transcript. Likewise, a nega-
tive association suggests that the binding and presentation
of a peptide is effective and elicits a successful T-cell cyto-
toxic response with destruction of leukemia cells.
The aim of this study was to analyze the disease associa-
tion between HLA alleles and bcr-abl fusion transcripts in
greater detail than has so far been studied. First, we
assessed the HLA association with a particular bcr-abl tran-
script, i.e., b2a2 or b3a2 or e1a2, and not with CML in
general. Second, unlike earlier studies that were limited to
low-resolution allele typing, this study used high-resolu-
tion typing for HLA class II genes.
Methods
A total of 189 patients comprising of 163 with CML and
26 with ALL, all with t(9;22) (q34;q11) and known HLA
types, were included in this study. Of these patients, 28
expressed b2a2 and b3a2 transcripts, while 68 expressed
the b2a2 transcript, 76 the b3a2 transcript, and 17 the
e1a2 transcript. The comparisons were made with healthy,
potential bone marrow donors that were HLA typed at our
laboratory. 376 donors were typed for HLA class I and 267
donors for HLA class II. The donor population is a multi-
racial group of both related and unrelated prospective
bone-marrow donors with no significant clinical history.
The gene frequencies are not at odds with reported gene
frequencies in general populations for prevailing races.
We decided to use our internal gene frequencies from this
donor population for three reason: First, it is a multiracial
group in which no racial bias was made, more representa-
tive of the population the reported patients came from
than any specific racial group typically used to determine
HLA gene frequencies. Second, it is a group for which
high-resolution high-quality typing is readily available
making it possible to evaluate allelic gene frequency dif-
ferences, rather than differences at the serologic low-reso-
lution level. Third, it is a group for which not only the
HLA phenotype is available, but also the genotype, that is,
the haplotypes were determined in each case, particularly
in regard to class II genes.
Typing of bcr-abl fusion transcripts by reverse-
transcriptase PCR
Leukocytes prepared by erythrocyte lysis of bone marrow
aspirate (1–2 ml) and peripheral blood (10 ml) samples
collected in ethylene diamine tetraacetic acid were used
for RNA isolation. Total RNA was isolated by using Trizol
reagent (Invitrogen Lifetechnologies, USA) according to the
manufacturer's instruction. The integrity of RNA was
determined by gel electrophoresis prior to reverse tran-
scription (RT). Total RNA (1–5 µg) from samples with
intact 28 s and 18 s RNA was converted to cDNA by using
random hexamers and Superscript II reverse transcriptase
(Invitrogen Lifetechnologies) according to the recommenda-
tions of the manufacturer.
Each sample was amplified in duplicate for bcr-abl in a
multiplex RT-PCR using an abl  primer in combination
with bcr b2- and e1-specific primers [17]. The t(9;22)-pos-
itive cell lines KBM7, K562, and B15, which carry b2a2,
b3a2, and e1a2 fusion genes, respectively, served as posi-
tive controls. [18,19] The HL60 cell line was used as neg-
ative control.
HLA typing
HLA typing was performed by molecular methods. For
class I, HLA typing was done at the intermediate-resolu-
tion level by using enzyme linked probe hybridizationBMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/25
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assay with sequence-specific oligonucleotide probe
(ELPHA-SSOP) (Biotest, Germany). The sequence-specific
oligonucleotide probes were used to identify polymor-
phic sequence motifs. The hybridization between probe
and target DNA from the series of amplified PCR products
was detected by a method adapted from the protein
enzyme linked immunosorbent assay (ELISA) technique.
For class II, HLA typing was done at the high-resolution
level by using the sequence specific primers (SSP) (Geno-
vision, USA or Pel-freez, USA). The technique uses a battery
of known sequence specific primers to amplify specific
alleles or group of alleles. This typing method is based on
the fact that a completely matched primer will be used
more efficiently in the PCR reaction than a partially mis-
matched primer. The electrophoresis bands generated
were compared with the kit standards.
Statistical analysis
HLA gene frequencies (not phenotype frequency) were
calculated in two different populations: (1) Healthy indi-
viduals typed as potential candidates for donating bone
marrow; and (2) Patients diagnosed as having CML or ALL
in whom bcr-abl transcripts were identified.
The sizes of the gene pools of these populations for HLA
typing are shown in Table 1. In order to obtain more accu-
rate gene frequencies, the largest population of typed
donors was used. This resulted in a larger population for
class I genes (376 individuals) than for class II genes (268
individuals). The frequencies of the HLA-A, -B, -DRB1 and
-DQB1 alleles for the three groups of CML patients with
different bcr-abl transcripts were compared with their gene
frequencies in the healthy donor group. The frequencies
of HLA alleles in patients were evaluated in 192 chromo-
somes of patients with b2a2 transcirpts (96 individuals,
68 with only b2a2 and 28 with both b2a2 and b3a2); 208
chromosomes of patients with b3a2 (104 individuals, 76
with only b3a2 and 28 with both b2a2 and b3a2); and 34
chromosomes of patients with e1a2 (17 individuals). The
comparisons were made by calculating the relative risks.
Chi-squares were also calculated to assess the statistical
significance of the differences. With (ν) = (r-1)(c-1) = 1
degree of freedom and a significance level of α = 0.05
needed to reject the null hypothesis, the χ2 statistic must
be > 3.84. Since ours is an international referral center
with a patient population of diverse racial backgrounds, it
was not possible to compare the patient data with the
standard HLA frequencies based on ethnicity. We there-
fore used the healthy bone marrow donor population for
comparison.
The binding scores were calculated on the basis of the
amino acid sequence of the peptide and the HLA mole-
cule as described elsewhere [20-22]. The sequences of
e1a2, b3a2, and b2a2 junctional peptides are EGAFHG-
DAEALQRPVAS [10,15], ATGFKQSSKALQRPVAS [23],
and IPLTINKEEALQRPVAS [24].
Results and discussion
Our findings are summarized in Tables 2,3,4, which
include only statistically significant observations with χ2 >
3.84, corresponding to a significance level of p < 0.05. Rel-
ative risk > 1 indicates that a particular HLA allele is more
frequent in a patient population with a particular tran-
script than within the corresponding healthy population.
Relative risk < 1 indicates a negative association, with a
gene frequency significantly smaller than in the corre-
sponding general population. Significant negative associ-
ations with b2a2 were seen with HLA-A*02, -A*68, -B*14,
-B*15, -B*40, -DQB1*0303, -DQB1*0603, and -
DRB1*1101. Significant positive association was seen
with HLA-A*01, -A*23, -A*66, -B*37, -B*38, -B*42, -
B*45, -B*49, -B*53, -B*56, -B*62, -DQB1*0201, -
DQB1*0402, -DQB1*0609, -DRB1*0301, -DRB1*0302,
-DRB1*0901, -DRB1*1001, -DRB1*1201, -DRB1*1202,
and -DRB1*1503 (Table 2).
Significant negative associations with b3a2 were seen with
HLA-A*68, -B*14, -B*15, -DQB1*0303, and
DRB1*0701. Significant positive association were seen
with HLA-A*25, -B*37, -B*49, -B*51, -B*53, -B*56, -
B*60, -B*62, -DQB1*0609, -DRB1*0405, -DRB1*0802, -
DRB1*0901, -DRB1*1001, and -DRB1*1503 (Table 3).
Significant negative associations with e1a2 were seen with
HLA-A*02, -A*68, -B*14, and -DRB1*0401. Significant
positive association were seen with HLA-A*01, -A*11, -
A*26, -B*08, -B*49, -B*53, -B*62, -DQB1*0201, -
DQB1*0502, -DRB1*0301, -DRB1*0802, and
DRB1*1601 (Table 4).
The relative maximum binding scores of various peptides
with the HLA types are also shown in the corresponding
tables. The scores are particularly high for HLA-A*02, -
A*68, -B*14, and -B*53 (all with b2a2), HLA-A*68, -
B*14, and -B*62 (all with b3a2) and HLA-A*01, -A*02, -
B*08, and -B*14 (all with e1a2).
Table 1: 
HEALTHY DONORS* CML + ALL*
HLA Class I: 752 b2a2: 192
HLA Class II: 538 b3a2: 208
e1a2: 34
*Numbers of HLA genes available in the different populations to 
calculate HLA allele frequencies (not the number of individuals in 
these populations taking into account that an individual carries two 
genes for each loci).BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/25
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Interestingly, 1.6% of patients with t(9;22) (q34;q11)
lacked HLA-DRB3, -DRB4, and -DRB5 alleles. This con-
trasts with the healthy group of which only 0.13% lacked
these alleles. The 2 × 2 contingency table analysis yielded
a likelihood ratio of 25 and a χ2 of 42.8, indicating a sta-
tistical significance of p < 0.001.
The presence of bcr-abl transcripts in patients with leuke-
mia appears to be associated with both HLA class I and II
alleles. In general, exogenous antigens are processed to
peptides in the endocytic compartment and are presented
by HLA class II to CD4+ T cells. On the other hand, endog-
enous peptides resulting from cleavage of proteins are
transferred by the transport-associated proteins to the
endocytoplasmic reticulum. In the endocytoplasmic retic-
ulum, these peptides bind to newly synthesized HLA class
I molecules, and the resulting complexes are transported
to the cell surface to be recognized by CD8+ T cells. It has
been shown however, that endogenous antigens can be
processed by both class I and class II HLA molecules [25-
27]. The bcr-abl  transcripts in leukemia cells would be
endogenous peptides and would normally be presented
by HLA class I molecules. In our study and other studies
cited in Table 5, negative associations with both HLA class
I and II alleles have been seen. A possible explanation is
that the bcr-abl transcripts are presented by both HLA class
I and class II.
There are published reports of both negative and positive
associations of bcr-abl  transcripts with HLA class I and
class II alleles (Table 5). By a positive association it is
meant that individuals having a particular bcr-abl tran-
script are more likely to be endowed with a particular HLA
phenotype. By a negative association it is meant that indi-
viduals showing a particular bcr-abl  transcript are less
likely to have a given HLA phenotype. Most of these stud-
ies were done with low-resolution HLA typing data. Post-
huma et al claimed that HLA-A3 and -B8 are associated
with a diminished risk of development of CML [28]. On
the basis of a large multi-center data from the European
bone marrow transplant program (n = 1462), they also
claimed that HLA-DR4 is associated with diminished risk
Table 2: b2a2 association with HLA Class I and II in leukemia patients and healthy donors with statistical analysis
HLA ALLELE LEUKEMIA PATIENTS* HEALTHY DONORS* RELATIVE RISK CHI-SQUARE BINDING SCORE
A 01 32 78 1.76 6.35 3
A 02 50 275 0.63 6.66 6
A 23 9 13 2.85 6.12
A 66 5 4 5.09 7.15
A 68 5 107 0.16 19.20 6
B 14 9 99 0.32 10.88 7
B 15 6 60 0.37 5.56
B 37 3 2 5.94 4.87
B 38 7 11 2.55 3.89
B 40 3 64 0.17 11.22
B 42 3 1 11.90 7.40
B 45 5 5 3.99 5.48
B 49 3 2 5.94 4.87
B5 39 3 1 2 . 2 6 2 2 . 3 8 9
B 56 4 2 7.97 7.99
B 62 6 0 45060000.00 23.62 0
DQB1 0201 23 36 1.89 5.29
DQB1 0303 4 30 0.36 3.90
DQB1 0402 10 9 3.22 6.95
DQB1 0603 8 50 0.42 5.11
DQB1 0609 4 0 21480000.00 11.25
DRB1 0301 23 36 1.89 5.29
DRB1 0302 3 0 16110000.00 8.43
DRB1 0901 4 1 11.40 7.47
DRB1 1001 5 2 7.15 7.41
DRB1 1101 10 53 0.50 3.89
DRB1 1201 3 0 16110000.00 8.43
DRB1 1202 2 0 10740000.00 5.61
DRB1 1503 5 1 14.33 10.13
*Figures shown are the gene frequencies. For a significance level of = 0.05 needed to reject the null hypothesis, the chi square statistic must be > 
3.84BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/25
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of CML. They compared patient data with data from unaf-
fected individuals from the registry of bone marrow
donors worldwide (n = 500596). The patients and con-
trols were matched by country. The odds ratio for HLA-
DR3 was 0.86 (95% confidence interval CI 0.75–0.98)
and for -DR4 combined with -B8, was 0.84 (95% CI 0.72–
0.98) [29]. A limitation of this study was that no high-res-
olution class II typing was done. It was also assumed that
all the CML patients expressed the p210 protein, which is
present in a majority but not all cases of CML. Pawelec
and Wagner have questioned their claim on the basis of its
reliance on low-resolution typing and have stressed the
need for high-resolution HLA typing [30]. Our present
study not only used high-resolution HLA class II typing
but also included all three types of bcr-abl  transcripts
(b2a2, b3a2, and e1a2). Significant negative associations
with p < 0.05 was seen with HLA-A*02 (b2a2, e1a2), -
A*68 (b2a2, b3a2, e1a2), -B*14 (b2a2, b3a2, e1a2), -
B*15 (b2a2, b3a2), -B*40 (b2a2), -DQB1*0303 (b2a2,
b3a2), -DQB1*0603 (b2a2), -DRB1*0401 (e1a2), -
DRB1*0701 (b3a2), and -DRB1*1101 (b2a2). In a simi-
lar study using high-resolution HLA-DRB1 typing, Yasu-
kawa  et al reported positive association with HLA-
DRB1*1201 (b2a2), and -DRB1*0403, -DRB1*0802, -
DRB1*1403, DRB1*1405 (all with b3a2), and a negative
association with -DRB1*0405, -DRB1*08032, -
DRB1*1502 (all with b2a2) and -DRB1*08032, and -
DRB1*1501 (both with b3a2) in a Japanese population
(Table 5) [36]. However, the study included only 50 cases
and included no patients with the e1a2 transcript. Fur-
thermore, association with HLA-DQB1 typing was not
assessed. Our study had a larger population (n = 189)
though of mixed ethnicity. The common findings of the
two studies include positive association with HLA-
DRB1*1201 (b2a2) and -DRB1*0802 (b3a2). There were
no common HLA alleles with a negative association.
Tabe 6 shows HLA class II haplotypes with increased fre-
quency in patients with the various types of bcr-abl
transcripts.
The patients in our study had HLA class II typing that
included HLA-DRB1*, -DRB3*, -DRB4*, -DRB5*, -
DQB1* and -DPB1*. We included in our results the statis-
tical data on HLA-DRB1* and -DQB1*. Our study is
unique among published reports by incorporating HLA-
DQB1 data. Unlike HLA-DRB1 and -DQB1, HLA-DRB3, -
DRB4, and -DRB5 are not expressed by all individuals;
expression depends on the haplotype. An interesting
observation was the fact that the frequencies of absence of
HLA-DRB3, -DRB4 and -DRB5 phenotype were higher in
the patient pool then in the healthy donors. This could
imply that HLA-DRB3, -DRB4, and -DRB5 alleles are asso-
ciated with bcr-abl transcript presentation.
The bcr-abl transcripts can generate a T-cell response [31-
34]. Successful allogeneic, autologous, and HLA-identical
sibling dendritic cell immunization strategies against
CML with b3a2-p210 peptide have also been tried, with
generation of T-cell response [35-39]. There are reports of
Table 3: b3a2 association with HLA Class I and II in leukemia patients and healthy donors with statistical analysis
HLA ALLELE LEUKEMIA PATIENTS* HEALTHY DONORS* RELATIVE RISK CHI-SQUARE BINDING SCORE
A 25 4 4 3.74 3.94
A 68 7 107 0.21 17.80 8
B 14 5 99 0.16 19.57 5
B 15 5 60 0.28 8.04
B 37 5 2 9.22 10.27
B4 96 2 1 1 . 1 2 1 3 . 5 0
B 51 13 19 2.57 6.99 4
B 53 5 3 6.14 7.91 3
B 56 3 2 5.48 4.34
B 60 8 0 60080000.00 29.13
B 62 6 0 45060000.00 21.80 8
DQB1 0303 4 30 0.33 4.62
DQB1 0609 3 0 16110000.00 7.78
DRB1 0405 4 2 5.25 4.51
DRB1 0701 21 99 0.50 7.72
DRB1 0802 3 1 7.84 4.43
DRB1 0901 4 1 10.51 6.78
DRB1 1001 4 2 5.25 4.51
DRB1 1503 3 1 7.84 4.43
*Figures shown are the gene frequencies. For a significance level of = 0.05 needed to reject the null hypothesis, the chi square statistic must be > 
3.84BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/25
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successful in vitro generation of HLA-DRB1*1501-
restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lym-
phocytes in ALL [40,41]. The restriction was confirmed by
loss of the cytotoxic effect in the presence of anti-HLA-DR
and preservation of the effect when anti-HLA class I was
used.
Conclusions
It seems that bcr-abl peptides are presented by many differ-
ent HLA types. The negative association could occur
because the early leukemogenic events are contained by a
T-cell cytotoxic response and this prevents disease prolif-
eration. A positive association could mean that the HLA
molecules do not present the bcr-abl transcripts. We hold
Table 4: e1a2 association with HLA Class I and II in leukemia patients and healthy donors with statistical analysis
HLA ALLELE LEUKEMIA PATIENTS* HEALTHY DONORS* RELATIVE RISK CHI-SQUARE BINDING SCORE
A 01 9 78 3.18 8.91 5
A 02 6 275 0.38 4.76 8
A 11 4 27 3.65 5.93 3
A 26 3 16 4.54 6.37
A 68 0 107 0.00 5.48 3
B 08 6 45 3.36 7.27 7
B 14 0 99 0.00 5.13 7
B 49 1 2 11.35 6.11
B 53 1 3 7.56 4.15 3
B 62 3 0 22530000.00 66.52 2
DQB1 0201 7 36 3.61 8.85
DQB1 0502 2 4 8.33 8.12
DRB1 0301 7 36 3.61 8.85
DRB1 0401 0 56 0.00 3.93
DRB1 0802 1 1 16.24 6.95
DRB1 1601 2 2 16.72 13.96
*Figures shown are the gene frequencies. For a significance level of = 0.05 needed to reject the null hypothesis, the chi square statistic must be > 
3.84.
Table 5: Published data on HLA association with bcr-abl transcripts
b2a2 b3a2 e1a2
POSITIVE ASSOCIATION DRB1*1201 [42] DRB1*0423 [42]
DRB1*0802 [42]
DRB1*1423 [42]
DRB1*1425 [42]
NEGATIVE ASSOCIATION DRB1*0425 [42] DRB1*08032 [42]
DRB1*08032 [42] DRB1*1501 [42]
DRB1*1502 [42]
PEPTIDE PRESENTATION A2.1 [43] A2.1 [43] DR4 [29]
A3 [28, 44, 45] A3 [28, 44, 45, 47] DRB1*1501 [40, 41]
A11 [28, 44] A11 [28, 44, 47]
B8 [28, 44] B8 [28, 44, 47]
DR1 [23, 30, 46] DR1 [23, 30, 46]
DR2 [30, 46] DR2 [30, 46]
DR3 [30, 46] DR3 [30, 46]
DR4 [30, 46] DR4 [30, 46]
DR11 [44]
DRB1*0101 [23]
DRB1*0301 [48]
DRB1*0423 [46]
DRB1*0901 [42]BMC Cancer 2004, 4 http://www.biomedcentral.com/1471-2407/4/25
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the theoretical assumption that HLA-restricted T-cell cyto-
toxicity performs an immunosurveillance role in the
pathogenesis of bcr-abl-transcript leukemias. Should this
assumption hold, knowledge of the HLA association with
different  bcr-abl  transcripts would have diagnostic and
prognostic implications. It would also help in improving
strategies of immunization with the bcr-abl  peptides
against t(9;22) (q34;q11) leukemia.
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